Prostate cancer screening improves quality of life by catching disease before it spreads

	Tweet

Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment, compared to men who were treated prior to the use of routine screening, according to the first study-of-its-kind presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

In 1993, routine prostate cancer screening became widely implemented through the use of a prostate specific antigen (PSA) test that was able to catch and diagnose the disease earlier. The test measures the level of prostate specific antigen, a protein produced by the prostate that can be measured through a simple blood test. Increased levels of PSA may be a sign of prostate cancer.

Opponents of routine screening have argued that routine prostate cancer screening has not resulted in a meaningful improvement in survival. However, researchers in this study considered that the best way to measure the screening’s effectiveness may be to examine its ability to decrease metastatic prostate cancer within 10 years after treatment for a screened population. 

"Our study shows that routine screening not only improves the patient’s quality of life by stopping metastatic disease, but it also decreases the burden of care for this advanced disease that must be provided by the health care system,” Chandana Reddy, M.S., lead author of the study and a senior biostatistician at the Cleveland Clinic in Cleveland, said. “This demonstrates that the PSA test is extremely valuable in catching the disease earlier and allowing men to live more productive lives after treatment.”

Metastatic prostate cancer is when the cancer has spread beyond the prostate and surrounding area to other places in the body. This advanced stage of the disease is not curable.

The retrospective study was based on data from 1,721 prostate cancer patients who were treated with either radiation therapy or surgery to remove the prostate gland and surrounding tissue at the Cleveland Clinic between 1986 and 1996. To assess the impact of screening, the patients were divided into two groups according to when they were treated: a prescreening era (1986-1992) or a post-screening era (1993-1996). Patients were also classified as having high-, intermediate- or low-risk disease to determine which groups may have benefitted from prostate cancer screening.

The study shows that within each of the three risk groups, patients treated in the prescreening era were significantly more likely to develop metastatic disease within 10 years of treatment, compared to men in the post-screening era.

###

For more information on radiation therapy for prostate cancer, visit http://www.rtanswers.org.

The abstract, “The Impact of Screening for Prostate Cancer on the Development of Metastatic Disease after Treatment,” will be presented at 11:00 a.m. on Monday, November 1, 2010. To speak to the lead author of the study, Chandana Reddy, M.S., please call Beth Bukata or Nicole Napoli October 31 – November 2, 2010, in the ASTRO Press Room at the San Diego Convention Center at 619-525-6313 or 619-525-6314. You may also e-mail them at or .

###

Contact: Beth Bukata

703-839-7332
American Society for Radiation Oncology

RELATED STORIES:
Study examines the use of a novel suprapubic catheter in suprapubic prostatectomy   Hopkins Prostate Cancer Experts Available   Accurate Prostate Cancer Diagnosis Depends on Biopsy Location   Early prostate cancer detection, screening: No benefit for men with low baseline PSA value   How Advanced Prostate Cancer Becomes Resistant to Androgen-deprivation Therapy   Cancer in sister affects black men’s cancer risk   Should the UK lower the age for prostate cancer detection?   Omega-3s cut risk of advanced prostate cancer   Artificial Light at Night: Higher Risk of Prostate Cancer   Genetic factors implicated in survival gap for breast, ovarian or prostate cancer   No Evidence That Widely Prescribed Statins Protect Against Prostate Cancer   Prostate cancer clinical stage does not predict recurrence   Faulty Gene Linked to Prostate Cancer Risk   Artificial Light at Night: Higher Risk of Prostate Cancer   Prostate cancer screening: More harm than good?   Scientists Link Variations in Growth-Factor Gene to Risk of Prostate Cancer   Men who stay trim less apt to get prostate cancer   U.S. Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening   Many prostate cancer patients receive improper or ‘mismatched’ therapies   STD confirmed to be associated with increased risk of prostate cancer   Scientists unravel role of fusion gene in prostate cancer   Screening for Prostate Cancer May Not Reduce Men’s Risk of Death

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]